NSAIDs and colorectal cancer prevention (original) (raw)

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 1981;41:1954–1957.
    PubMed CAS Google Scholar
  2. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989;157:175–179.
    Article PubMed CAS Google Scholar
  3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232–235.
    PubMed CAS Google Scholar
  4. Myaki M, Konishi M, Kikuchi-Yanoshita R, Enomoto M, Tanaka K, Iwama T, et al. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res 1994;54:3011–3020.
    Google Scholar
  5. Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000;130:641–649.
    Article PubMed CAS Google Scholar
  6. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Taketo MM, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803–809.
    Article PubMed CAS Google Scholar
  7. Iwama T, Akasu T, Utsunomiya J, Muto T. Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial. Int J Clin Oncol 2006;11:133–139.
    Article PubMed CAS Google Scholar
  8. Moher D, Schulz KF, Atman DG; for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191–1194.
    Article PubMed CAS Google Scholar
  9. Gann PH. Low-dose aspirin and evidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1182–1184.
    Article Google Scholar
  10. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883–890.
    Article PubMed CAS Google Scholar
  11. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891–899.
    Article PubMed CAS Google Scholar
  12. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K-M, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873–884.
    Article PubMed CAS Google Scholar
  13. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674–1682.
    Article PubMed CAS Google Scholar
  14. Giardiello FM, Offenhaus JA, Tersmette AC, Hylind LM, Krush AJ, Brensinger JD, et al. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut 1996;38:578–581.
    Article PubMed CAS Google Scholar
  15. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath LD, et al. Primary chemoprevention of familial adenomatous polyposisi with sulindac. N Engl J Med 2002;346:1054–1059.
    Article PubMed CAS Google Scholar
  16. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;242:1946–1952.
    Article Google Scholar
  17. Higuchi T, Iwama I, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003;9:4756–4760.
    PubMed CAS Google Scholar
  18. Solomon SD, McMurray JJV, Pfeffer MS, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071–1080.
    Article PubMed CAS Google Scholar
  19. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med 2007;146:365–375.
    PubMed Google Scholar
  20. Meyskens FL, Gerne EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5:945–951.
    PubMed CAS Google Scholar
  21. Nie L, Feng W, Diaz R, Gratton MA, Doley KJ, Yamoah EN. Functional consequences of polyamine synthesis inhibition by DFMO: cellular mechanisms for DFMO-mediated ototoxicity. J Biol Chemist 2005;M409856200; www.jbc.org.
  22. Gerne EW, Meiskens FL, Goldschmidt S, Lance P, Pelot D. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. Amino Acids 2007;33:189–195.
    Article CAS Google Scholar
  23. Barry ELR, Baron JA, Bhat S, Grau MV, Burke CA, Sandler RS, et al. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J Nat Cancer Inst 2006;98:1494–1500.
    Article PubMed CAS Google Scholar

Download references